Tag Archives: Refraction Media

New science magazine INGENUITY launched

Featured image above: At the launch of INGENUITY with UNSW Dean of Engineering Mark Hoffman, Refraction Media cofounders Karen Taylor-Brown and Heather Catchpole, and UNSW Engineering’s senior communications advisor Wilson da Silva

INGENUITY, a new science magazine focusing on the frontiers of engineering research at UNSW and with a global distribution, was launched on Tuesday by UNSW’s Dean of Engineering, Mark Hoffman.

“We are, without question, a powerhouse of engineering research in Australia,” said Hoffman. “With nine schools, 32 research centres and participating or leading 10 Cooperative Research Centres, we do truly amazing research – among the world’s best. And we work with more than 500 partners in industry and government to bring the fruits of that research to society.

“We have capacity to do more, as many potential research partners in Australia and overseas are not necessarily aware of the breadth and depth of what we do,” he added. “If we are to have the greatest impact in the world at large, as a university and as engineers, we need to get our research out to the world.  And the creation of INGENUITY is part of that effort.”

Hoffman said the magazine was one of a number of initiatives UNSW Engineering is pursuing to enhance the Faculty’s global impact and its academic and research excellence.

“In May, we hosted the first Ingenuity Fellow, a journalist-in-residence program for overseas science journalists. Our inaugural recipient was Rebecca Morelle, global science correspondent for BBC News in London, and she spent three weeks on-campus meeting some of our best minds and most impressive innovators. And last month, we held a sold-out public event with Peter Norvig, Research Director at Google, talking about Google’s approach to artificial intelligence and machine learning.

“We mean to not just be the leading engineering faculty in the country but, in a global industry, to be seen as one of the great engineering faculties of the world,” he concluded.

Through engaging storytelling by some of the country’s finest science writers, stylish design and beautiful photography, INGENUITY will bring to life the Faculty’s work in areas like quantum computing, bionic vision, solar energy, water and city environments, artificial intelligence, biomedical instrumentation, robotics, advanced polymers, space research, materials and membranes, cyber security and sustainable design.

The free magazine is being distributed to senior executives of Australia’s largest corporations, federal and state parliamentarians and senior government officials, scientific and industry collaborators of UNSW’s Faculty of Engineering globally, as well as science and technology journalists worldwide. The print edition is also being distributed to Australian embassies and trade offices overseas, and at the biennial World Conference of Science Journalists and the Annual Meeting of the American Association for the Advancement of Science.

The magazine is produced by specialist custom publishing house Refraction Media, whose clients include Google, the CRC Association, the Office to the Chief Scientist and ANSTO, and who was named Best Small Publisher in 2015 at the annual Publish Awards.

“Quality long-form journalism in science and technology is hard to come by in Australia,” said Wilson da Silva, the faculty’s senior communications advisor and former editor-in-chief of COSMOS magazine, which he co-founded with Alan Finkel, now Australia’s Chief Scientist. “There’s a wealth of great research stories to tell at UNSW, and we hope that everyone, including the general public, will enjoy the quality writing in INGENUITY and the great stories of Australian research excellence it has to tell.”

How to receive INGENUITY:

This information was first shared by UNSW Engineering on 5 July 2017. 

Science Meets Business summit

Teachers and postdocs key to innovation

Featured image above: a series of four panels discussed STEM and innovation at the Science Meets Business summit

Australia should ‘hang its head in shame’ over our lack of support for teachers, says Ian Chubb AC, the ex-Chief Scientist of Australia, at the second national Science Meets Business event in Melbourne.

The gathering of CEO’s, board members, government, research leaders and start-ups focussed on improving collaboration and innovation in Australia’s STEM (science, technology, engineering and maths) and startup sectors.

As well as ensuring a strong STEM talent pipeline by improving support for teachers, a ‘simple but elegant’ national, industry-led PhD program is key to an innovative future, ANSTO CEO Adi Paterson said at the summit.

The summit heard how developing visible pathways to careers and skilling up students across humanities and STEM was important both to creating startups and improving existing business.

Labour’s Senator Kim Carr and Liberal Assistant Minister Craig Laundy brought the political grunt to a richly experienced series of four panels that covered taking startups to small to medium enterprises; Australia’s tech expertise; improving collaboration between research, government and industry; and looking for Australia’s ‘next big thing’.

The Science Meets Business summit is run annually by Science and Technology Australia. Science Meets Business publishers Refraction Media support the summit as media partner.

There is a need to refocus what we mean by innovation away from “hipster app developers” Senator Carr said, and towards innovation in existing business.

“It’s not possible to foster innovation without substantial investment in science and research,” said Senator Carr.

In a rare bipartisan agreement between the Liberal and Labour factions, The Honorable Craig Laundy MP also called out the need to solve problems in current business in a largely off-the-cuff speech that emphasised his own background as a publican, where innovation could be a new way to clean the taps – which could have involved three staff previously.

Laundy pointed out that there was a need for business to meet science as well as ‘science meets business’.

Developing language to bring together business, investment, researchers and students was one of the areas where Australia could be doing better, the summit heard.

“Innovation is not startups. We’re talking about the transformation of a whole economy,” said Adrian Turner, CEO of Data 61 and chair of the Cyber Security Growth Centre.

Turner went on to say that Australia must look away from Silicon Valley and towards its own opportunities where deep science meets fast-paced entrepreneurship.

Tech capability, biotech, agricultural innovation and defence were some of the strengths which set Australia apart from the rest of the world, the Science Meets Business summit heard.

“We need to lift the scale of our business-science ambition,” Turner said.

Got an opinion? Share your thoughts here or connect with us on Twitter.

– Heather Catchpole

You might also enjoy:

Innovation breathes new life into old business

Excellence in Innovation Awards

Top 25 R&D Spin-off Awards

Featured image above: Top 25 winners accepting their awards with Refraction Media‘s CEO, Karen Taylor. Left to right: executives from iCetana, Refraction Media, Vaxxas, Fibrotech Therapeutics and SmartCap Technologies. Credit: Dave Dwyer Video Production and Photography

The Cooperative Research Centres Association (CRCA) presented the Top 25 R&D Spin-off Awards last week at their annual conference, The Business of Innovation. The awards honoured the Top 25 Science Meets Business R&D spin-off companies – a list of Australian businesses that have successfully moved their R&D from the lab to the marketplace.

The Top 25 companies were compiled by Refraction Media and supported by data from Thomson ReutersThey were judged by a panel comprising of: Dr Peter Riddles, biotechnology expert and director on many start-up enterprises; Dr Anna Lavelle, CEO and Executive Director of AusBiotech; and Tony Peacock, Chief Executive of the Cooperative Research Centres Association.

For each company, the panel considered total market value, annual turnover, patents awarded and cited, funding and investment, growth year-on-year, social value, overseas expansion and major partnerships.

Top 25 R&D spin-offs

Top 25 R&D spin-offs

For a country that makes up just 0.3% of the world’s population, Australia packs a heavyweight punch in science – generating 3.9% of the world’s research publications. However taking that research to market has proved a broader challenge.

Fostering the commercialisation of research success and encouraging collaboration between industry and researchers is at the forefront of the government’s renewed focus on scientific innovation, with over $1.1 billion earmarked to kickstart the “ideas boom” as part of the National Innovation and Science Agenda.

“Collaboration is key to turning Australian ideas into viable and lucrative commercial products and services,” says Christopher Pyne, Minister for Industry, Innovation and Science, adding that high-tech knowhow plus innovative R&D will drive jobs and wealth in the future.

“We must capitalise on the opportunities that are presenting themselves in the economic transition taking place in Australia by being agile, innovative and creative,” Pyne says.

He notes a range of measures, including the $155 million Industry Growth Fund and the R&D Tax Incentive program, are supporting firms to innovate and drive investment into new high-growth industry sectors.

From industry-funded ventures to university spin-offs and rising star start-ups, these are the Science Meets Business Top 25 Australian research and development spin-off companies.

Click here to see the full list, or continue reading. For further insights from the leaders of the Top 25 R&D spin-off companies, read their interviews on attracting venture capital, learning from overseas marketsgetting past the valley of death, overcoming major start-up challenges and starting up.


FIBROTECH THERAPEUTICS PTY LTD

 

TYPE: NOT LISTED

CEO: Darren Kelly

SOLD FOR: US$557.5 million

INNOVATION RATIO*: 0.15


Fibrotech develops novel drug candidates to treat fibrosis (tissue scarring) associated with chronic conditions such as heart failure, kidney and pulmonary disease, and arthritis. The company spun out of research by Professor Darren Kelly at the University of Melbourne in 2006, and its principal asset is a molecule, FT011, which helps prevent kidney fibrosis associated with diabetes. In May 2014, in one of Australia’s biggest biotech deals at the time, Fibrotech was acquired by Shire, a Dublin-based pharmaceutical company, for an initial payment of US$75 million. Further payments, based on a series of milestones, will bring the total value of the sale to US$557.5 million, and the deal was awarded Australia’s best early stage venture capital deal in 2014. At the time of the sale, FT011 was in Phase 1b trials for the treatment of renal impairment in diabetics – a market worth US$4 billion annually.

*Innovation ratio = patents published/cited

Founder, CEO & director of Fibrotech Therapeutics, Professor Darren Kelly
Founder, CEO & director of Fibrotech Therapeutics, Professor Darren Kelly

SPINIFEX PHARMACEUTICALS PTY LTD

 

TYPE: LISTED

MARKET VALUE: $264 million

CEO/President: Dr Tom McCarthy

INNOVATION RATIO: 0.13

SOLD FOR: acquired by Novartis for US$200 million up-front payment plus milestone payments


Spinifex Pharmaceuticals was launched in 2005 to commercialise chronic pain treatments developed by Professor Maree Smith of The University of Queensland. Pharmaceuticals giant Novartis acquired the company in 2015 for a total of US$725 million, based on the promising results in Phase 1b and Phase 2 clinical trials. Spinifex’s treatment targets nerve receptors on peripheral nerves rather than pain receptors in the brain, making it possible to treat the pain from causes such as shingles, chemotherapy, diabetes and osteoarthritis without central nervous system side-effects such as tiredness and dizziness.

Dr Tom McCarthy_intext
CEO/President of Spinifex Pharmaceuticals, Dr Tom McCarthy

ADMEDUS LTD

 

TYPE: LISTED

MARKET VALUE: $61.88 million

COO: Julian Chick

INNOVATION RATIO: 0.02

REVENUE: $10.2 million


Admedus is a diversified healthcare company with interests in vaccines, regenerative medicine, and the sale and distribution of medical devices and consumables. Currently, the company is developing vaccines for herpes simplex virus and human papillomavirus based on Professor Ian Frazer’s groundbreaking vaccine technology. In the regenerative medicine field, Admedus is the vendor of CardioCel®, an innovative single-ply bio-scaffold that can be used in the treatment of congenital heart deformities and complex heart defects.


BIG 3 – RESMED LTD

 

TYPE: LISTED

MARKET VALUE: $7.85 billion

CEO: Michael J Farrell

INNOVATION RATIO: 0.02

REVENUE: $1.68 billion


For more than 25 years, ResMed has been a pioneer in the treatment of sleep-disordered breathing, obstructive pulmonary disease and other chronic diseases. The company was founded in 1989 after Professor Colin Sullivan and University of Sydney colleagues developed nasal continuous positive airway pressure – the first successful, non-invasive treatment for obstructive sleep apnoea. Today, the company employs more than 4000 people in over 100 countries, delivering treatment to millions of people worldwide.


BIODIEM LTD

 

TYPE: NOT LISTED

CEO/Executive Director: Julie Phillips

INNOVATION RATIO: 0.22

REVENUE: $203,809


BioDiem specialises in the development and commercialisation of vaccines and therapies to treat infectious diseases. The Live Attenuated Influenza Virus vaccine technology provides a platform for developing vaccines, including one for both seasonal and pandemic influenza. BioDiem’s subsidiary, Opal Biosciences, is developing BDM-I, a compound that offers a possible avenue for the treatment of infectious diseases that resist all known drugs.


VAXXAS PTY LTD

 

TYPE: NOT LISTED

CEO/Director: David Hoey


Vaxxas is pioneering a needle-free vaccine delivery system, the Nanopatch, which delivers vaccines to the abundant immunological cells just under the skin’s surface. Preclinical studies have shown that vaccines are effective with as little as one-hundredth of a conventional dose when delivered via a Nanopatch. In 2014, Vaxxas was selected by the World Economic Forum as a Technology Pioneer, based on the potential of Nanopatch to transform global health.


6 ACRUX DDS PTY LTD

 

TYPE: LISTED

MARKET VALUE: $122.39 million

CEO: Michael Kotsanis

INNOVATION RATIO: 0.01

REVENUE: $25.4 million

Biotech company Acrux was incorporated in 1998 after researchers at Monash University developed an effective new spray-on drug delivery technology that improved absorption through the skin and nails. In 2010, Acrux struck a US$335 million deal with global pharmaceutical company Eli Lilly for AxironTM, a treatment for testosterone deficiency in men. It was the largest single product licensing agreement in the history of Australian biotechnology.

CEO of Acrux, Michael Kotsanis
CEO of Acrux, Michael Kotsanis

PHARMAXIS LTD

 

MARKET VALUE: $72.9 million

CEO: Gary J Phillips

INNOVATION RATIO: 0.76

REVENUE: $59.25 million

Listed on the ASX in 2003, Pharmaxis has two products on the market: Bronchitol, a treatment for cystic fibrosis; and Aridol, a lung function test to diagnose and assess asthma. In 2015, Pharmaxis sold the rights to a treatment for the liver condition nonalcoholic steatohepatitis, to Boehringer Ingelheim in a deal that could be worth US$750 million.

Garyphillips_in text
CEO of Pharmaxis, Gary J Phillips

OPTHEA PTY LTD

 

TYPE: LISTED

MARKET VALUE: $42.80 million

CEO/MD: Dr Megan Baldwin

INNOVATION RATIO: 0.01

REVENUE: $939,008

With a focus on ophthalmology, Opthea’s main product is OPT-302 – a treatment for wet age-related macular degeneration – which is currently in a Phase 1/2a clinical trial. Wet macular degeneration is the leading cause of blindness in the Western world. Opthea was formerly known as Circadian Technologies, acting as a biotechnology investment fund before transitioning to developing drugs in 2008.


BENITIC BIOPHARMA LTD

 

TYPE: LISTED

MARKET VALUE: $63.01 million

CEO: Greg West

INNOVATION RATIO: 0.14

REVENUE: $1.37 million

Benitec Biopharma’s leading product is DNA-directed RNA interference (ddRNAi) – a platform for silencing unwanted genes as a treatment for a wide range of genetic conditions. ddRNAi has broad applications, and can assist with conditions as diverse as neurological, infectious and autoimmune diseases, as well as cancers. The company’s current focus inludes hepatitis B and C, wet age-related macular degeneration and lung cancer.


10 CATAPULT GROUP INTERNATIONAL LTD

 

TYPE: LISTED

MARKET VALUE: ~$256 million

CEO: Shaun Holthouse

REVENUE: $11.8 million

Catapult makes athletic performance monitoring systems using global and local positioning technologies for more than 750 elite teams, universities and institutions worldwide. The technology was commercialised in 2006 and its IPO in December 2014 raised more than $12 million from investors – including from US billionaire Mark Cuban.

CEO of Catapult, Shaun Holthouse
CEO of Catapult, Shaun Holthouse

11 SMARTCAP TECHNOLOGIES PTY LTD

 

CEO: Dush Wimal

INNOVATION RATIO: 0.03

TYPE: NOT LISTED

Using a wearable electroencephalograph (EEG), SmartCap monitors driver fatigue by measuring changes in brain activity without significant discomfort or inconvenience. It notifies users when they are fatigued and what time of day they’re most at risk. SmartCap was formally EdanSafe, a CRCMining spin-off company.

CEO of Smartcap, Dush Wimal
CEO of Smartcap Technologies, Dush Wimal

BIG 3 – COCHLEAR LTD

 

TYPE: LISTED

MARKET VALUE: $4.8 billion

INNOVATION RATIO: 0.05

CEO/PRESIDENT: Chris Smith

REVENUE: $925.6 million

Cochlear delivers hearing to over 400,000 people worldwide through products like the cochlear implant. Pioneered by the University of Melbourne’s Professor Graeme Clark and developed with assistance from The HEARing CRC, the bionic devices were first successfully implanted by the Royal Victorian Eye and Ear Hospital for people with moderate to profound hearing loss. The global company now employs 2800 staff and assists people in 100 countries.

CEO/President of Cochlear, Chris Smith
CEO/President of Cochlear, Chris Smith

12 ECOULT PTY LTD

 

TYPE: NOT LISTED

CEO: John Wood

Founded by the CSIRO in 2007 to commercialise the UltraBattery, Ecoult was acquired by the East Penn Manufacturing Company in 2010. The UltraBattery makes it possible to smooth out the peaks and troughs in renewable power, functioning efficiently in a state of partial charge for extended periods.


13 QUICKSTEP HOLDINGS LTD

 

MARKET VALUE: $87.09 million

CEO/MD: David Marino

INNOVATION RATIO: 0.04

REVENUE: $39.51 million

Composite materials company Quickstep was founded in 2001 to commercialise their patented manufacturing process. Working with the aerospace, automotive and defence industries, Quickstep supplies advanced carbon fibre composite panels for high technology vehicles. In 2015, the company increased its manufacturing capacity, establishing an automotive production site in Victoria in addition to their aerospace production site in NSW.


14 ENGENEIC LTD

 

TYPE: NOT LISTED

JOINT CEOs/DIRECTORS: Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt

MARKET VALUE: $178 million

INNOVATION RATIO: 0.03

EnGeneIC’s cancer treatment platform, the EnGeneIC Dream Vector (EDVTM), is a first-in-class cytoimmunotherapy.

The EDV is a nanocell mechanism for delivering drugs and functional nucleic acids and can target tumours without coming into contact with normal cells, greatly reducing toxicity. Above all, the EDV therapeutic stimulates the adaptive immune response, thereby enhancing anti-tumour efficacy. More than 260 patents support the technology, developed entirely by EnGeneIC, giving the company control over its application.

Joint CEOs and directors of EnGeneIC, Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt
Joint CEOs and directors of EnGeneIC, Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt

15 SNAP NETWORK SURVEILLANCE PTY LTD

 

TYPE: NOT LISTED

CEO: Simon Langsford

CTO/FOUNDER: Dr Henry Detmold

Snap’s FMx is a unique approach to video surveillance that forms cameras into a network based on artificial intelligence that learns relationships between what the cameras can see. It enables advanced real-time tracking and easier compilation of video evidence. Developed at the University of Adelaide’s Australian Centre for Visual Technologies, the system is operational at customer sites in Australia, Europe and North America.


16 ORTHOCELL LTD

 

TYPE: LISTED

MARKET VALUE: $32.89 million

MD: Paul Anderson

INNOVATION RATIO: 0.81

REVENUE: $1.69 million

Orthocell develops innovative technologies for treating tendon, cartilage and soft tissue injuries. Its Ortho-ATI™ and Ortho-ACI™ therapies, for damaged tendons and cartilage, use the patient’s cells to assist treatments. Its latest product, CelGro™, is a collagen scaffold for soft tissue and bone regeneration.


17 REDFLOW

 

TYPE: LISTED

MARKET VALUE: $111.3 million

CEO: Stuart Smith

INNOVATION RATIO: 0.16

REVENUE: $265,436

As the demand for effective energy storage grows, RedFlow’s zinc-bromide flow batteries are gaining attention. RedFlow has outsourced its manufacturing to North America to keep up with demand, while the company’s research and development continues in Brisbane.

CEO of Redflow, Stuart Smith
CEO of Redflow, Stuart Smith

18 MINIFAB PTY LTD

 

TYPE: NOT LISTED

CEO: Dr Erol Harvey

INNOVATION RATIO: 2

Since 2002, precision engineering company MiniFAB has completed more than 900 projects for customers across the globe. MiniFAB provides a complete design and manufacturing service, and has developed polymer microfluidic and microengineered devices for medical and diagnostic products, environmental monitoring, food packaging and aerospace.


19 RAYGEN RESOURCES PTY LTD

 

TYPE: NOT LISTED

CEO: Robert Cart

INNOVATION RATIO: 0.74

RayGen’s power generation method involves an ultra high efficiency array of photovoltaic cells, which receive focused solar energy from heliostats (mirrors) that track the sun, resulting in high performance at low cost. In December 2014, RayGen and the University of New South Wales (UNSW) collaborated to produce the highest ever efficiency for the conversion of sunlight into electricity. The independently verified result of 40.4% efficiency for the advanced system is a game changer, now rivalling the performance of conventional fossil power generation.

Robert Cart_intext
CEO of RayGen Resources, Robert Cart

BIG 3 – CSL LTD

 

TYPE: LISTED

MARKET VALUE: $44.93 billion

CEO/MD: Paul Perreault

INNOVATION RATIO: 0.05

REVENUE: US$5.6 million

CSL is Australia’s largest biotechnology company, employing over 14,000 people across 30 countries. The company began in 1916, when the Commonwealth Serum Laboratories was founded in Melbourne. It was incorporated in 1991, and listed on the ASX in 1994. Since that time, CSL has acquired established plasma protein maker CSL Behring, and Novartis’ influenza vaccine business, and has become a global leader in the research, manufacture and marketing of biotherapies.


20 CARNEGIE WAVE ENERGY LTD

 

TYPE: LISTED

MARKET VALUE: $88.38 million

MD: Dr Michael Ottaviano

INNOVATION RATIO: 0.21

REVENUE: $1.72 million

Carnegie Wave Energy’s CETO technology converts ocean swell into zero-emission renewable power and desalinated freshwater. Ten years of research at test sites off the coast of Western Australia, along with over $100 million in local and foreign investment, has helped grow the company’s global profile.

A recent £2 million grant from the Scottish government boosted stock prices.


21 DYESOL LTD

 

TYPE: LISTED

MD: Richard Caldwell

MARKET VALUE: $110.13 million

INNOVATION RATIO: 0.12

REVENUE: $1.44 million

Dyesol Limited (ASX: DYE) is a renewable energy supplier and leader in Perovskite Solar Cell (PSC) technology – 3rd Generation photovoltaic technology. The company’s vision is to create a viable low-cost source of electricity with the potential to disrupt the global energy supply chain and energy balance.

MD of Dyesol, Richard Caldwell
MD of Dyesol, Richard Caldwell

22 EVOGENIX LTD

 

TYPE: NOT LISTED

SOLD FOR: $207 million

INNOVATION RATIO: 0.11

EvoGenix began as a startup in 2001 to commercialise EvoGene™, a powerful method of improving proteins, developed by the CSIRO and the CRC for Diagnostics. It acquired US company Absalus Inc in 2005, then merged with Australian biotechnology company Peptech in 2007, to form Arana Therapeutics. In 2009, Cephalon Inc bought the company for $207 million.


23 MURADEL PTY LTD

 

TYPE: NOT LISTED

CEO/MD: David Lewis

REVENUE: $4.18 million

With a vision to create sustainable energy through renewable biofuels, Muradel is a joint venture between the University of Adelaide, Murdoch University and SQC Pty Ltd. Their $10.7 million Demonstration Plant converts algae and biosolids into green crude oil. Muradel has plans for upgrades to enable the sustainable production of up to 125,000 L of crude oil, and to construct a commercial plant capable of supplying over 50 megalitres of biocrude from renewable feedstocks.


24 iCETANA

 

TYPE: NOT LISTED

CEO: Gary Pennefather

INNOVATION RATIO: 0.05

iCetana’s ‘iMotionFocus’ technology employs machine learning to determine what is the ‘normal’ activity viewed by each camera in a surveillance system and alerts operators when ‘abnormal’ events occur. This enables fewer operators to monitor more cameras with greater efficiency.


25 PHYLOGICA LTD

 

TYPE: LISTED

MARKET VALUE: $33.82 million

CEO: Dr Richard Hopkins

INNOVATION RATIO: 0.09

Phylogica is a drug discovery service, and the owner of Phylomer® Libraries, the largest and most structurally diverse suite of natural peptides. It has worked with some of the world’s largest drug companies, including Pfizer and Roche, to uncover drug candidates.


The Top 25 Science Meets Business R&D spin-off companies was written by Refraction Media in consultation with universities, industry and funding bodies, and supported by data from Thomson Reuters.

The research compiled by Refraction was judged by a panel comprising of: Dr Peter Riddles, biotechnology expert and director on many start-up enterprises; Dr Anna Lavelle, CEO and Executive Director of AusBiotech; and Tony Peacock, Chief Executive of the Cooperative Research Centres Association. The panel considered the following: total market value, annual turnover, patents awarded and cited, funding and investment, growth year-on-year, social value, overseas expansion and major partnerships.

2015 Publish Awards

Science beats sport at the 2015 Publish Awards

Photo from left: Refraction founders Heather Catchpole and Karen Taylor-Brown, with Production Manager Heather Curry and Publishing Co-ordinator Jesse Hawley.

Refraction Media, a Sydney-based publishing start-up, was announced Australia’s Best Small Publisher at the 2015 Publish Awards. Specialising in STEM (science, technology, engineering and maths), Refraction Media came out on top in a category that included sport, luxury and lifestyle at the industry’s night-of-nights.

The jurors at the 2015 Publish Awards said:

“Refraction Media outclassed the other entrants. For a start up operation that’s only two years old, the company has managed to capitalise on an untapped market with incredible skill and with many clever, innovative and successful media streams.”

Publishing’s leaders, representing titles such as Vogue, the Australian Women’s Weekly and Gourmet Traveller, competed for accolades at the 2015 Publish Awards alongside youth disrupters such as Junkee, Vice and Pedestrian.tv while business and industry like In the Black and Australian Pharmacist brought their A-game.

Amongst the glitz and glamour at the 2015 Publish Awards, science valiantly flew its flag with New Scientist‘s Australasia reporter Michael Slezak a finalist for Journalist of the Year (Consumer/Custom) and COSMOS magazine’s Editor-in-Chief, Dr Elizabeth Finkel, a finalist for Single Article of the year for her piece ‘The buzz around brain stimulation‘.

With a strong presence on the main stage and by sharing the language and aesthetics of mass publishers, science publishers are taking science out of a niche audience and placing it firmly at the centre of a dynamic industry of interactivity, sharing and scrolling.

As science, technology, engineering and maths (STEM) becomes more visual, accessible and dynamic, especially to Australia’s youth, engagement and participation rates will climb. This future STEM-skilled workforce is critical to Australia’s future prosperity. STEM graduates will facilitate innovation and collaboration.

Refraction Media fills a unique niche in the market that connects science and technology with the general public. Since its launch in 2013, Refraction has printed over half a million magazines across eight titles, shared 16 in-depth science study guides with schools, produced 13 3D animations, edited 17 scientific white papers, developed two e-learning platforms and created the worldwide, one-and-only virtual tour of a nuclear reactor.

Refraction produce two websites, for news at the nexus of research and industry, www.sciencemeetsbusiness.com.au; and careerswithcode.com.au, which aims to inspire high school students to combine their passion – whether it’s music, arts, business, sports or the environment – with STEM skills to create the careers of the future.

Refraction Media has demonstrated that rather than being ‘niche’, specialising in science uncovers a world of opportunity and discovery.